LLY241213C690000
- 69.00
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
Eli Lilly Unusual Options Activity
Eli Lilly Says Imlunestrant Improved Progression-Free Survival in Phase 3 Breast Cancer Study
Express News | Ro Works With Lilly to Streamline Patient Access to Authentic Zepbound Single-Dose Vials by Integrating With Lilly's Pharmacy Channel
Express News | Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer
Eli Lilly and Co will conduct research on whether weight loss drugs can effectively control addictive behavior.
On December 11, Glonghui reported that Eli Lilly and Co's CEO Dave Ricks stated that the company will begin studying whether its best-selling weight loss drug can also effectively control addiction behaviors such as alcoholism, smoking, and drug use. Ricks mentioned in a meeting that these medications are 'antidotes to pleasure' and may temporarily free patients from dependence on drugs. Some doctors have already indicated that this drug can help alleviate drug addiction. Novo-Nordisk A/S also indicated earlier this year that it plans to research drug addiction.
Express News | Ro: Vials to Be Available With on-Label Prescription From a Ro-Affiliated Provider via Integration With Lillydirect Self-Pay Pharmacy Channel
Bank of America: Resuming coverage of Eli Lilly and Co, rating it as 'Buy'.
Bank of America resumes coverage on Eli Lilly and Co, assigning a "Buy" rating with a Target Price of $997.
Bank of America resumes coverage of Eli Lilly and Co with a target price of $997.
Gelonghui, December 11｜Bank of America: Resumes coverage on Eli Lilly and Co, gives a "Buy" rating with a target price of $997. (Gelonghui)
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Eli Lilly and Co CEO: The future policy focus is on tax and regulatory reform, as well as Pharmaceutical affordability.
On December 11, according to Reuters, Eli Lilly and Co CEO David Ricks stated on Tuesday that tax and regulatory reform and pharmaceutical affordability are the company's policy priorities under the Trump administration. Last week, Trump met with Ricks and industry lobbying group PhRMA's CEO in Florida, with Pfizer CEO Albert Bourla also participating in the meeting. Ricks did not disclose details of the discussion nor provide more information regarding the specific reforms he is targeting. He mentioned that the regulatory situation in the USA has negatively impacted the pharmaceutical industry over the past four years.
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio (Abemaciclib) in Patients With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts